Relationship Between Severity of Adverse Events of Afatinib and Its Pharmacokinetics and Pharmacogenomics for EGFR Mutation-Positive Non-Small Cell Lung Cancer

被引：0
|
作者：
Gomyo, T. [1 ]
Iihara, H. [2 ]
Hayashi, H. [3 ]
Endo, J. [1 ]
Ito, F. [1 ]
Yansase, K. [1 ]
Kaito, D. [1 ]
Sasaki, Y. [1 ]
Sakai, C. [1 ]
Fukuda, Y. [3 ]
Hirose, C. [2 ]
Sugiyama, T. [1 ]
Suzuki, A. [2 ]
Ohno, Y. [1 ]
机构：
[1] Gifu Univ, Grad Sch Med, Gifu, Japan
[2] Gifu Univ Hosp, Gifu, Japan
[3] Gifu Pharmaceut Univ, Gifu, Japan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3936
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ADVERSE EVENTS COSTS ASSOCIATED WITH ERLOTINIB OR AFATINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR MUTATION-POSITIVE TUMOURS
    Isla, D.
    De Castro, J.
    Juan Vidal, O.
    Grau, S.
    Orofino, J.
    Gordo, R.
    Rubio-Terres, C.
    Rubio-Rodriguez, D.
    VALUE IN HEALTH, 2015, 18 (07) : A429 - A429
  • [2] Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Lilenbaum, Rogerio A.
    Horn, Leora A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (5.5): : 672 - 674
  • [3] Afatinib in EGFR mutation positive advanced non-small cell lung cancer
    Davies, R. S.
    Brewster, A. E.
    Button, M. R.
    Lester, J. F.
    LUNG CANCER, 2016, 91 : S22 - S22
  • [4] Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
    Keiko Nakao
    Shinji Kobuchi
    Shuhei Marutani
    Ayano Iwazaki
    Akihiro Tamiya
    Shunichi Isa
    Kyoichi Okishio
    Masaki Kanazu
    Motohiro Tamiya
    Tomonori Hirashima
    Kimie Imai
    Toshiyuki Sakaeda
    Shinji Atagi
    Scientific Reports, 9
  • [5] Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
    Nakao, Keiko
    Kobuchi, Shinji
    Marutani, Shuhei
    Iwazaki, Ayano
    Tamiya, Akihiro
    Isa, Shunichi
    Okishio, Kyoichi
    Kanazu, Masaki
    Tamiya, Motohiro
    Hirashima, Tomonori
    Imai, Kimie
    Sakaeda, Toshiyuki
    Atagi, Shinji
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [6] Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
    Watanabe, Satomi
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (11)
  • [7] Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Funazo, T.
    Yasuda, Y.
    Hirai, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2416 - S2416
  • [8] Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
    Zhou, Jia-Ying
    Liu, Si-Yang
    Wu, Yi-Long
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) : 589 - 599
  • [9] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
    Meinrenken, Susanne
    PNEUMOLOGIE, 2018, 72 (04): : 246 - 246
  • [10] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
12345